Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carol Garwood

Clinical Nurse Specialist, Adult Health Columbus, OH Clinical Nurse Specialist

NPI 1598044737 CMS profile 10473461

85 McNaughten Rd, Suite 350, Columbus, OH 43213

Open in the dashboard

General payments

$3,675

85 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carol Garwood of Columbus, OH is reported in the CMS Open Payments database as having received $3,675 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Clinical Nurse Specialist, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $470 20
2024 General $1,798 23
2023 General $985 26
2022 General $359 11
2021 General $63 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carol Garwood
  • Clinical Nurse Specialist, Adult Health median
  • Middle half of Clinical Nurse Specialist, Adult Health
  • National median

In program year 2025, general payments to Carol Garwood were reported at $470. Among 446 Clinical Nurse Specialist, Adult Health profiles paid that year, the median was $193 and the middle half received between $61 and $597.

Show as a table
Year Carol Garwood Clinical Nurse Specialist, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $63 $133 $48–$445 $132
2022 $359 $163 $57–$526 $149
2023 $985 $173 $64–$597 $160
2024 $1,798 $171 $54–$575 $164
2025 $470 $193 $61–$597 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $1,631 17 payments
  2. AstraZeneca Pharmaceuticals LP $804 23 payments
  3. Novo Nordisk Inc $266 10 payments
  4. Lexicon Pharmaceuticals, Inc. $262 4 payments
  5. Merck Sharp & Dohme Corporation $154 5 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $136 7 payments
  7. Novartis Pharmaceuticals Corporation $129 8 payments
  8. Abbott Laboratories $93 1 payment
  9. Pfizer Inc. $72 1 payment
  10. Bayer HealthCare Pharmaceuticals Inc. $63 4 payments
  11. Other $67 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,706 80 payments
  2. Travel and Lodging $890 3 payments
  3. Education $79 2 payments
Products named General payments · program years 2021–2025
  1. RESONATE EL ICD VR $1,064 4 payments
  2. FARXIGA $638 18 payments
  3. Inpefa $238 3 payments
  4. Wegovy $205 6 payments
  5. VERQUVO $203 8 payments
  6. BRILINTA $156 5 payments
  7. General - Therapies General - Therapies_CRM $140 1 payment
  8. General - Therapies General - Therapies_IC $138 1 payment
  9. LEQVIO $99 6 payments
  10. ENTRESTO $99 6 payments
  11. Other $921 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

2,757

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$984,701

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

33.1%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 346 $425,744
Farxiga Dapagliflozin Propanediol Brand 296 $291,394
Jardiance Empagliflozin Brand 211 $230,342
Dapagliflozin Dapagliflozin Propanediol Brand 22 $14,187
Torsemide Generic 229 $6,422
Metoprolol Succinate Generic 242 $3,069
Midodrine Hcl Generic 15 $2,260
Spironolactone Generic 384 $2,116
Furosemide Generic 450 $1,891
Eplerenone Generic 24 $1,497

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$45,242

Medicare's payments for the services billed

Medicare patients

285

Average age 76

Services billed

602

134 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Chronic kidney disease 65%
Atrial fibrillation 61%
Arthritis 59%
Diabetes 55%
COPD 47%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $193
$193 296 —
Inpefa
  • Lexicon Pharmaceuticals, Inc. $101
$101 — —
VYNDAMAX
  • PFIZER INC. $72
$72 — —
WAINUA
  • AstraZeneca Pharmaceuticals LP $55
$55 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $53
$53 211 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Adult Health in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record